Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial

DOI record: { "DOI": "10.3389/fphar.2022.1096853", "ISSN": [ "1663-9812" ], "URL": "http://dx.doi.org/10.3389/fphar.2022.1096853", "abstract": "<jats:p><jats:bold>Background:</jats:bold> Quercetin, a natural polyphenol with demonstrated broad-spectrum antiviral, anti-inflammatory, and antioxidant properties, has been proposed as an adjuvant for early-stage coronavirus disease 2019 (COVID-19) infection.</jats:p><jats:p><jats:bold>Objective:</jats:bold> To explore the possible therapeutic effect of quercetin in outpatients with early-stage mild to moderate symptoms of COVID-19.</jats:p><jats:p><jats:bold>Methods:</jats:bold> This was an open-label randomized controlled clinical trial conducted at the department of medicine, King Edward Medical University, Lahore, PK. Patients were randomized to receive either standard of care (SC) plus an oral quercetin supplement (500 mg Quercetin Phytosome®, 1st week, TDS: 2nd week, BDS) (<jats:italic>n</jats:italic> = 50, quercetin group) or SC alone (<jats:italic>n</jats:italic> = 50, control group).</jats:p><jats:p><jats:bold>Results:</jats:bold> After one week of treatment, patients in the quercetin group showed a speedy recovery from COVID-19 as compared to the control group, i.e., 34 patients (vs. 12 in the control group) tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (<jats:italic>p</jats:italic> = 0.0004), and 26 patients (vs. 12 in the control group) had their COVID-19-associated acute symptoms resolved (<jats:italic>p</jats:italic> = 0.0051). Patients in the quercetin group also showed a significant fall in the serum lactate dehydrogenase (LDH) mean values i.e., from 406.56 ± 183.92 to 257.74 ± 110.73 U/L, <jats:italic>p</jats:italic> = 0.0001. Quercetin was well-tolerated by all the 50 patients, and no side effects were reported.</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> Our results, suggest the possible therapeutic role of quercetin in early-stage COVID-19, including speedy clearance of SARS-CoV-2, early resolution of the acute symptoms and modulation of the host’s hyperinflammatory response.</jats:p><jats:p><jats:bold>Clinical Trial Registration:</jats:bold><jats:ext-link>clinicaltrials.gov</jats:ext-link>, identifier NCT04861298</jats:p>", "alternative-id": [ "10.3389/fphar.2022.1096853" ], "author": [ { "affiliation": [], "family": "Di Pierro", "given": "Francesco", "sequence": "first" }, { "affiliation": [], "family": "Khan", "given": "Amjad", "sequence": "additional" }, { "affiliation": [], "family": "Iqtadar", "given": "Somia", "sequence": "additional" }, { "affiliation": [], "family": "Mumtaz", "given": "Sami Ullah", "sequence": "additional" }, { "affiliation": [], "family": "Chaudhry", "given": "Muhammad Nabeel Akbar", "sequence": "additional" }, { "affiliation": [], "family": "Bertuccioli", "given": "Alexander", "sequence": "additional" }, { "affiliation": [], "family": "Derosa", "given": "Giuseppe", "sequence": "additional" }, { "affiliation": [], "family": "Maffioli", "given": "Pamela", "sequence": "additional" }, { "affiliation": [], "family": "Togni", "given": "Stefano", "sequence": "additional" }, { "affiliation": [], "family": "Riva", "given": "Antonella", "sequence": "additional" }, { "affiliation": [], "family": "Allegrini", "given": "Pietro", "sequence": "additional" }, { "affiliation": [], "family": "Recchia", "given": "Martino", "sequence": "additional" }, { "affiliation": [], "family": "Zerbinati", "given": "Nicola", "sequence": "additional" } ], "container-title": "Frontiers in Pharmacology", "container-title-short": "Front. Pharmacol.", "content-domain": { "crossmark-restriction": true, "domain": [ "frontiersin.org" ] }, "created": { "date-parts": [ [ 2023, 1, 13 ] ], "date-time": "2023-01-13T05:32:47Z", "timestamp": 1673587967000 }, "deposited": { "date-parts": [ [ 2023, 1, 13 ] ], "date-time": "2023-01-13T05:32:50Z", "timestamp": 1673587970000 }, "indexed": { "date-parts": [ [ 2023, 1, 14 ] ], "date-time": "2023-01-14T06:17:46Z", "timestamp": 1673677066891 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 1, 13 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 1, 13 ] ], "date-time": "2023-01-13T00:00:00Z", "timestamp": 1673568000000 } } ], "link": [ { "URL": "https://www.frontiersin.org/articles/10.3389/fphar.2022.1096853/full", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1965", "original-title": [], "prefix": "10.3389", "published": { "date-parts": [ [ 2023, 1, 13 ] ] }, "published-online": { "date-parts": [ [ 2023, 1, 13 ] ] }, "publisher": "Frontiers Media SA", "reference": [ { "DOI": "10.1016/j.ijbiomac.2020.07.235", "article-title": "Structural stability of SARS-CoV-2 3CL pro and identification of quercetin as an inhibitor by experimental screening", "author": "Abian", "doi-asserted-by": "publisher", "first-page": "1693", "journal-title": "Int. J. Biol. Macromol.", "key": "B1", "volume": "164", "year": "2020" }, { "DOI": "10.1016/j.foodchem.2021.131594", "article-title": "Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols", "author": "Bahun", "doi-asserted-by": "publisher", "first-page": "131594", "journal-title": "Food. Chem.", "key": "B2", "volume": "373", "year": "2022" }, { "DOI": "10.3389/fphar.2021.704205", "article-title": "The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: Lessons learned from major clinical studies", "author": "Chakraborty", "doi-asserted-by": "publisher", "first-page": "704205", "journal-title": "Front. Pharmacol.", "key": "B3", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.bmc.2006.09.014", "article-title": "Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): Structure-activity relationship studies reveal salient pharmacophore features", "author": "Chen", "doi-asserted-by": "publisher", "first-page": "8295", "journal-title": "Bioorg Med. Chem.", "key": "B4", "volume": "14", "year": "2006" }, { "DOI": "10.1093/jac/dkg291", "article-title": "In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids", "author": "Chiang", "doi-asserted-by": "publisher", "first-page": "194", "journal-title": "J. Antimicrob. Chemother.", "key": "B5", "volume": "52", "year": "2003" }, { "DOI": "10.3389/fimmu.2020.01451", "article-title": "Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19)", "author": "Colunga Biancatelli", "doi-asserted-by": "publisher", "first-page": "1451", "journal-title": "Front. Immunol.", "key": "B6", "volume": "11", "year": "2020" }, { "DOI": "10.1002/ptr.6887", "article-title": "A role for quercetin in coronavirus disease 2019 (COVID-19)", "author": "Derosa", "doi-asserted-by": "publisher", "first-page": "1230", "journal-title": "Phytother. Res.", "key": "B7", "volume": "35", "year": "2021" }, { "DOI": "10.1002/ptr.7309", "article-title": "Quercetin and its derivates as antiviral potentials: A comprehensive review", "author": "Di Petrillo", "doi-asserted-by": "publisher", "first-page": "266", "journal-title": "Phytother. Res.", "key": "B8", "volume": "36", "year": "2022" }, { "DOI": "10.2147/IJGM.S318720", "article-title": "Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: A prospective, randomized, controlled, and open-label study", "author": "Di Pierro", "doi-asserted-by": "publisher", "first-page": "2359", "journal-title": "Int. J. Gen. Med.", "key": "B9", "volume": "14", "year": "" }, { "DOI": "10.2147/IJGM.S318949", "article-title": "Potential clinical benefits of quercetin in the early stage of COVID-19: Results of a second, pilot, randomized, controlled and open-label clinical trial", "author": "Di Pierro", "doi-asserted-by": "publisher", "first-page": "2807", "journal-title": "Int. J. Gen. Med.", "key": "B10", "volume": "14", "year": "" }, { "DOI": "10.1016/j.ajem.2020.05.073", "article-title": "Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis", "author": "Henry", "doi-asserted-by": "publisher", "first-page": "1722", "journal-title": "Am. J. Emerg. Med.", "key": "B11", "volume": "38", "year": "2020" }, { "DOI": "10.3390/antiox11050876", "article-title": "The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature", "author": "Imran", "doi-asserted-by": "publisher", "first-page": "876", "journal-title": "Antioxidants (Basel)", "key": "B12", "volume": "11", "year": "2022" }, { "DOI": "10.1056/NEJMoa2031994", "article-title": "Baricitinib plus remdesivir for hospitalized adults with covid-19", "author": "Kalil", "doi-asserted-by": "publisher", "first-page": "795", "journal-title": "N. Engl. J. Med.", "key": "B13", "volume": "384", "year": "2020" }, { "DOI": "10.3390/pathogens10060758", "article-title": "Bioactive polyphenolic compounds showing strong antiviral activities against severe acute respiratory syndrome coronavirus 2", "author": "Kandeil", "doi-asserted-by": "publisher", "first-page": "758", "journal-title": "Pathogens", "key": "B14", "volume": "10", "year": "2021" }, { "DOI": "10.1038/s41586-020-2180-5", "article-title": "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor", "author": "Lan", "doi-asserted-by": "publisher", "first-page": "215", "journal-title": "Nature", "key": "B15", "volume": "581", "year": "2020" }, { "DOI": "10.1038/s41586-021-03995-1", "article-title": "Virus-induced senescence is a driver and therapeutic target in COVID-19", "author": "Lee", "doi-asserted-by": "publisher", "first-page": "283", "journal-title": "Nature", "key": "B16", "volume": "599", "year": "2021" }, { "DOI": "10.1021/acs.jafc.0c05064", "article-title": "Quercetin and its metabolites inhibit recombinant human angiotensin-converting enzyme 2 (ACE2) activity", "author": "Liu", "doi-asserted-by": "publisher", "first-page": "13982", "journal-title": "J. Agric. Food Chem.", "key": "B17", "volume": "68", "year": "2020" }, { "DOI": "10.3906/biy-2104-16", "article-title": "Treatment of COVID-19 patients with quercetin: A prospective, single center, randomized, controlled trial", "author": "Onal", "doi-asserted-by": "publisher", "first-page": "518", "journal-title": "Turk J. Biol.", "key": "B18", "volume": "45", "year": "2021" }, { "DOI": "10.1093/oxfordjournals.jbchem.a123251", "article-title": "Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids", "author": "Ono", "doi-asserted-by": "publisher", "first-page": "609", "journal-title": "J. Biochem.", "key": "B19", "volume": "108", "year": "1990" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Dexamethasone in hospitalized patients with covid-19", "doi-asserted-by": "publisher", "first-page": "693", "journal-title": "N. Engl. J. Med.", "key": "B20", "volume": "384", "year": "2021" }, { "DOI": "10.1016/S0140-6736(21)00676-0", "article-title": "Tocilizumab in patients admitted to hospital with COVID-19: A randomised, controlled, open-label, platform trial", "doi-asserted-by": "publisher", "first-page": "1637", "journal-title": "Lancet", "key": "B21", "volume": "397", "year": "2021" }, { "DOI": "10.3390/biomedicines9040375", "article-title": "Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: Implications for drug Design of quercetin analogs", "author": "Rizzuti", "doi-asserted-by": "publisher", "first-page": "375", "journal-title": "Biomedicines", "key": "B22", "volume": "9", "year": "2021" }, { "DOI": "10.3390/life12010066", "article-title": "Promising effects of 3-month period of quercetin Phytosome® supplementation in the prevention of symptomatic COVID-19 disease in healthcare workers: A pilot study", "author": "Rondanelli", "doi-asserted-by": "publisher", "first-page": "66", "journal-title": "Life (Basel)", "key": "B23", "volume": "12", "year": "2022" }, { "DOI": "10.1186/s12950-021-00268-6", "article-title": "Anti-inflammatory potential of Quercetin in COVID-19 treatment", "author": "Saeedi-Boroujeni", "doi-asserted-by": "publisher", "first-page": "3", "journal-title": "J. Inflamm. (Lond)", "key": "B24", "volume": "18", "year": "2021" }, { "DOI": "10.1016/j.ejphar.2021.174615", "article-title": "The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial", "author": "Shohan", "doi-asserted-by": "publisher", "first-page": "174615", "journal-title": "Eur. J. Pharmacol.", "key": "B25", "volume": "914", "year": "2022" }, { "DOI": "10.1016/j.ajem.2020.11.025", "article-title": "Lactate dehydrogenase level as a COVID-19 severity marker", "author": "Szarpak", "doi-asserted-by": "publisher", "first-page": "638", "journal-title": "Am. J. Emerg. Med.", "key": "B26", "volume": "45", "year": "2021" }, { "DOI": "10.1155/2016/5460302", "article-title": "Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-1β Production", "author": "Tőzsér", "doi-asserted-by": "publisher", "first-page": "5460302", "journal-title": "Mediators Inflamm.", "key": "B32", "year": "2016" }, { "key": "B27", "unstructured": "GRAS notices: Agency response letter GRAS notice No. GRN 000341\n Us Food and Drug Administration Letter\n 2010" }, { "DOI": "10.3390/v8010006", "article-title": "Quercetin as an antiviral agent inhibits influenza A virus (iav) entry", "author": "Wu", "doi-asserted-by": "publisher", "first-page": "6", "journal-title": "Viruses", "key": "B28", "volume": "8", "year": "2015" }, { "DOI": "10.1126/science.abb2762", "article-title": "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", "author": "Yan", "doi-asserted-by": "publisher", "first-page": "1444", "journal-title": "Science", "key": "B29", "volume": "367", "year": "2020" }, { "DOI": "10.1128/jvi.78.20.11334-11339.2004", "article-title": "Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells", "author": "Yi", "doi-asserted-by": "publisher", "first-page": "11334", "journal-title": "J. Virol.", "key": "B30", "volume": "78", "year": "2004" }, { "DOI": "10.14739/2310-1210.2021.5.231714", "article-title": "Efficacy of quercetin in patients with pneumonia associated with coronavirus disease (COVID-19)", "author": "Zupanets", "doi-asserted-by": "publisher", "first-page": "636", "journal-title": "Zaporizhia Med. J.", "key": "B31", "volume": "23", "year": "2021" } ], "reference-count": 32, "references-count": 32, "relation": {}, "resource": { "primary": { "URL": "https://www.frontiersin.org/articles/10.3389/fphar.2022.1096853/full" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology (medical)", "Pharmacology" ], "subtitle": [], "title": "Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.3389/crossmark-policy", "volume": "13" }